A Class of Iron Chelators with a Wide Spectrum of Potent Antitumor Activity That Overcomes Resistance to Chemotherapeutics

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2006 Sep 28

PMID 17003122

Citations 175

Authors

Megan Whitnall

Jonathan Howard

Prem Ponka

Des R Richardson

Affiliations

Soon will be listed here.

Abstract

Novel chemotherapeutics with marked and selective antitumor activity are essential to develop, particularly those that can overcome resistance to established therapies. Iron (Fe) is critical for cell-cycle progression and DNA synthesis and potentially represents a novel molecular target for the design of new anticancer agents. The aim of this study was to evaluate the antitumor activity and Fe chelation efficacy of a new class of Fe chelators using human tumors. In this investigation, the ligands showed broad antitumor activity and could overcome resistance to established antitumor agents. The in vivo efficacy of the most effective chelator identified, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT), was assessed by using a panel of human xenografts in nude mice. After 7 weeks, net growth of a melanoma xenograft in Dp44mT-treated mice was only 8% of that in mice treated with vehicle. In addition, no differences in these latter animals were found in hematological indices between Dp44mT-treated mice and controls. No marked systemic Fe depletion was observed comparing Dp44mT- and vehicle-treated mice, probably because of the very low doses required to induce anticancer activity. Dp44mT caused up-regulation of the Fe-responsive tumor growth and metastasis suppressor Ndrg1 in the tumor but not in the liver, indicating a potential mechanism of selective anticancer activity. These results indicate that the novel Fe chelators have potent and broad antitumor activity and can overcome resistance to established chemotherapeutics because of their unique mechanism of action.

Citing Articles

Targeting lysosomes by design: novel -acridine thiosemicarbazones that enable direct detection of intracellular drug localization and overcome P-glycoprotein (Pgp)-mediated resistance.

Kaya B, Smith H, Chen Y, Azad M, Russell T, Richardson V Chem Sci. 2024; .

PMID: 39165729 PMC: 11331336. DOI: 10.1039/d4sc04339a.

Iron metabolism: backfire of cancer cell stemness and therapeutic modalities.

Yu R, Hang Y, Tsai H, Wang D, Zhu H Cancer Cell Int. 2024; 24(1):157.

PMID: 38704599 PMC: 11070091. DOI: 10.1186/s12935-024-03329-x.

Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.

Villareal L, Falcon D, Xie L, Xue X Br J Cancer. 2024; 130(12):1904-1915.

PMID: 38693428 PMC: 11183190. DOI: 10.1038/s41416-024-02699-3.

Differential transmetallation of complexes of the anti-cancer thiosemicarbazone, Dp4e4mT: effects on anti-proliferative efficacy, redox activity, oxy-myoglobin and oxy-hemoglobin oxidation.

Dharmasivam M, Kaya B, Wijesinghe T, Richardson V, Harmer J, Gonzalvez M Chem Sci. 2024; 15(3):974-990.

PMID: 38239703 PMC: 10793205. DOI: 10.1039/d3sc05723b.

Desulfurization of thiosemicarbazones: the role of metal ions and biological implications.

Jimenez-Perez A, Fernandez-Farina S, Pedrido R, Garcia-Tojal J J Biol Inorg Chem. 2023; 29(1):3-31.

PMID: 38148423 DOI: 10.1007/s00775-023-02037-7.

References

OConnor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M . Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57(19):4285-300. View

Schneider E, Horton J, Yang C, Nakagawa M, Cowan K . Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994; 54(1):152-8. View

Richardson D, Tran E, Ponka P . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995; 86(11):4295-306. View

Richardson D . Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem. 2005; 12(23):2711-29. DOI: 10.2174/092986705774462996. View

Shen D, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S . Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem. 1986; 261(17):7762-70. View

Le N, Richardson D . Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004; 104(9):2967-75. DOI: 10.1182/blood-2004-05-1866. View

Yuan J, Lovejoy D, Richardson D . Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104(5):1450-8. DOI: 10.1182/blood-2004-03-0868. View

Ponka P, BOROVA J, NEUWIRT J, Fuchs O . Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979; 97(2):317-21. DOI: 10.1016/0014-5793(79)80111-8. View

Kurdistani S, Arizti P, Reimer C, Sugrue M, Aaronson S, Lee S . Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 1998; 58(19):4439-44. View

10.

Jiang Z, Lu X, Nelson V, Yang X, Pan W, Chen R . A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia. Proc Natl Acad Sci U S A. 2006; 103(5):1581-6. PMC: 1360591. DOI: 10.1073/pnas.0510573103. View

11.

Gao J, Richardson D . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98(3):842-50. DOI: 10.1182/blood.v98.3.842. View

12.

Richardson D, Bernhardt P . Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem. 1999; 4(3):266-73. DOI: 10.1007/s007750050312. View

13.

Kalinowski D, Richardson D . The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57(4):547-83. DOI: 10.1124/pr.57.4.2. View

14.

Le N, Richardson D . The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002; 1603(1):31-46. DOI: 10.1016/s0304-419x(02)00068-9. View

15.

Green D, Antholine W, Wong S, Richardson D, Chitambar C . Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res. 2001; 7(11):3574-9. View

16.

Bernhardt P, Caldwell L, Chaston T, Chin P, Richardson D . Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem. 2003; 8(8):866-80. DOI: 10.1007/s00775-003-0486-z. View

17.

Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A . Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 1993; 53(17):3968-75. View

18.

Becker E, Lovejoy D, Greer J, Watts R, Richardson D . Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol. 2003; 138(5):819-30. PMC: 1573713. DOI: 10.1038/sj.bjp.0705089. View

19.

Dunn L, Sekyere E, Suryo Rahmanto Y, Richardson D . The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis. 2006; 27(11):2157-69. DOI: 10.1093/carcin/bgl045. View

20.

Chandel N, McClintock D, Feliciano C, Wood T, Melendez J, Rodriguez A . Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000; 275(33):25130-8. DOI: 10.1074/jbc.M001914200. View